BKA Wealth Consulting Inc. acquired a new stake in  AbbVie Inc. (NYSE:ABBV – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor  acquired 1,240 shares of the company’s stock, valued at approximately $200,000.

Several other hedge funds also recently modified their holdings of ABBV. Red Tortoise LLC bought a new stake in shares of  AbbVie during the fourth quarter worth $27,000.  O Dell Group LLC boosted its holdings in  AbbVie by 108.7% in the third quarter. O Dell Group LLC now owns 192 shares of the company’s stock valued at $26,000 after acquiring an additional 100 shares during the last quarter.  My Personal CFO LLC bought a new position in  AbbVie during the fourth quarter worth about $32,000.  Align Wealth Management LLC bought a new position in  AbbVie during the 4th quarter worth approximately $27,000.  Finally, Oliver Lagore Vanvalin Investment Group increased its stake in  AbbVie by 85.3% in the third quarter. Oliver Lagore Vanvalin Investment Group now owns 202 shares of the company’s stock valued at $27,000 after purchasing an additional 93 shares in the last quarter. 67.71% of the stock is owned by institutional investors.

Several equities research analysts have commented on the stock. Guggenheim assumed coverage on shares of AbbVie in a research note on Tuesday, February 28th. They issued a “buy” rating and a $172.00 target price for the company. Piper Jaffray Companies increased their target price on shares of AbbVie from $157.00 to $163.00 and gave the stock an “overweight” rating in a report on Friday, February 10th. Argus cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. Atlantic Securities cut their price target on shares of AbbVie from $157.00 to $154.00 and set a “neutral” rating for the company in a research note on Friday, February 10th. Finally, Wolfe Research lowered shares of AbbVie from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 22nd. They noted that the move was a valuation call. Nine equities research analysts have rated the stock with a hold rating, six have issued  a buy rating and one  has given a strong buy rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $162.94.

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $149.53, for a total transaction of $3,738,250.00. Following the completion of the transaction, the executive vice president now directly owns 233,208 shares in the company, valued at $34,871,592.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Jeffrey Ryan Stewart sold 53,125 shares of the stock in a transaction on Monday, March 13th. The stock was sold at an average price of $152.28, for a total value of $8,089,875.00. Following the completion of the transaction, the executive vice president now directly owns 60,941 shares in the company, valued at approximately $9,280,095.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 25,000 shares of AbbVie stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $149.53, for a total value of $3,738,250.00. Following the transaction, the executive vice president now directly owns 233,208 shares in the company, valued at $34,871,592.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 178,268 shares of company stock valued at $27,231,420. Company insiders own  0.26% of the company’s stock.

NYSE:ABBV traded up $0.65 during mid-day trading on Wednesday, reaching $160.24. 780,691 shares of the company’s stock were exchanged, compared to its average volume of 5,954,490. AbbVie Inc. has a one year low of $134.09 and a one year high of $168.11. The firm has a market capitalization of $282.69 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 3.70 and a beta of 0.58. The business’s fifty day simple moving average is $155.31 and its two-hundred day simple moving average is $153.96. The company has a debt-to-equity ratio of 3.42, a quick ratio of 0.84 and a current ratio of 0.96.

AbbVie (NYSE:ABBV – Get Rating) last released its quarterly earnings results on Thursday, February 9th. The company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $3.54 by $0.06. AbbVie had a net margin of 20.39% and a return on equity of 154.52%. The business had revenue of $15.12 billion for the quarter, compared to analyst estimates of $15.30 billion. During the same period last year, the firm earned $3.31 earnings per share. AbbVie’s revenue for the quarter was up 1.6% compared to the same quarter last year.  Analysts anticipate that  AbbVie Inc. will post 10.92 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Stockholders of record on Friday, April 14th will be given a $1.48 dividend. This represents a $5.92 annualized dividend and a dividend yield of 3.69%. The ex-dividend date of this dividend is Thursday, April 13th. AbbVie’s payout ratio is presently 89.56%.

AbbVie, Inc is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson’s, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.